Humana Inc. $HUM Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board boosted its holdings in shares of Humana Inc. (NYSE:HUM - Free Report) by 8.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,533 shares of the insurance provider's stock after buying an additional 1,352 shares during the period. Public Sector Pension Investment Board's holdings in Humana were worth $4,375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in HUM. Cary Street Partners Investment Advisory LLC increased its position in Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after buying an additional 46 shares in the last quarter. Riverview Trust Co acquired a new stake in Humana during the 1st quarter worth about $34,000. Garde Capital Inc. acquired a new stake in Humana during the 1st quarter worth about $36,000. Zions Bancorporation National Association UT acquired a new stake in Humana during the 1st quarter worth about $37,000. Finally, Transce3nd LLC acquired a new stake in Humana during the 4th quarter worth about $38,000. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Price Performance

Shares of NYSE HUM traded up $1.8540 during trading on Wednesday, hitting $290.1040. The company had a trading volume of 1,247,622 shares, compared to its average volume of 1,729,705. The stock has a fifty day simple moving average of $244.92 and a two-hundred day simple moving average of $253.44. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $382.72. The firm has a market capitalization of $34.89 billion, a price-to-earnings ratio of 22.26, a price-to-earnings-growth ratio of 1.69 and a beta of 0.44. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. Humana's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter last year, the company earned $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. On average, research analysts expect that Humana Inc. will post 16.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on HUM. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $290.00 price target on shares of Humana in a research report on Thursday, May 1st. Piper Sandler lowered their price target on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research report on Thursday, July 31st. Robert W. Baird cut their price target on Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a research report on Friday, July 25th. Barclays set a $275.00 price target on Humana and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Finally, Oppenheimer increased their price target on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Seven investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. Based on data from MarketBeat.com, Humana currently has a consensus rating of "Hold" and a consensus price target of $281.43.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.